Updated August 3, 2026

How to Get Free or $35 Insulin in the US: Humulin, Basaglar, Lantus & More (August 2026)

Evan Brown
Written by Evan Brown
Prescription Savings Researcher
Dr. Megan Harris, MD Medically Reviewed by Dr. Megan Harris, MD
Healthcare Advocacy: This guide reflects manufacturer program terms and the Inflation Reduction Act's Medicare insulin cap as confirmed directly from Lilly, Sanofi, and Novo Nordisk's current program pages as of July 2026.
August 2026 Update

Insulin manufacturers continue offering affordability programs that reduce eligible patients' costs to $35 per month or less. Lilly's Insulin Value Program, Sanofi's Insulins Valyou Savings Program, and Novo Nordisk's MyInsulinRx all remain active for commercially insured and uninsured patients. Some uninsured patients may also qualify for completely free insulin through manufacturer Patient Assistance Programs if they meet income requirements. Eligibility and enrollment steps vary by manufacturer — the sections below break down each one by brand.

Quick Answer

In 2026, almost no one pays full price for insulin. Most patients pay $35/month or less through manufacturer programs. Uninsured and low-income patients can get insulin for $0 through Patient Assistance Programs (PAPs).

  • $35/month: Lilly Insulin Value Program (1-833-808-1234), Sanofi Valyou (1-800-633-1610), Novo Nordisk MyInsulinRx
  • $0 (free): Lilly Cares, Sanofi Patient Connection, Novo Nordisk PAP (1-866-310-7549) — income limits typically ~400% FPL
  • $25/vial: Generic insulin lispro via TrumpRx (no enrollment)
  • Medicare: $35 cap applies automatically, no deductible

Need exact prices by brand? See our complete 2026 insulin price comparison — 27 products with filterable prices.

Is Lantus discontinued in 2026?

No. Lantus (insulin glargine) has not been discontinued. Intermittent shortages of the SoloStar pen format have been reported since late 2025, but Lantus vials remain widely available. The confusion stems from the Semglee discontinuation on December 31, 2025 — Semglee was a biosimilar, not Lantus itself. If your pharmacy is out of Lantus pens, ask about Rezvoglar (interchangeable biosimilar) or unbranded insulin glargine.

See real-time Lantus availability by pharmacy →

Insulin Pen Shortage 2026: What to Know

As of August 2026, insulin vials remain widely available nationwide. However, pen formats have experienced intermittent stockouts at specific pharmacy chains:

If your pharmacy is out of pens: (1) Ask your prescriber to write a new prescription for vials + syringes — vials have been more stable; (2) Call a different pharmacy chain — shortages are often localized; (3) Ask about therapeutic substitution (e.g., Rezvoglar for Lantus, insulin lispro for Humalog).

Is There an Insulin Shortage in 2026?

As of August 2026, there is no nationwide shortage of insulin in the United States. The FDA has not placed any major insulin products on its drug shortage list. However, localized stockouts and specific-format shortages do occur:

Insulin availability status (August 2026)
Product Status Notes
Lantus SoloStar pens Intermittent shortages Some pharmacies out of stock; vials more available
Lantus vials Widely available Standard 10 mL vials in stock at most chains
Humalog / insulin lispro Widely available Both brand and generic fully stocked
NovoLog / Fiasp Widely available No shortage reported
Tresiba Widely available No shortage reported
Basaglar Widely available Not discontinued; KwikPen and vials in stock
Semglee Discontinued Dec 2025 Previously the cheapest biosimilar; no longer manufactured

What to do if your pharmacy is out: (1) Call a different chain — shortages are often localized; (2) Ask your pharmacist about therapeutic substitution to an in-stock equivalent (e.g., Rezvoglar for Lantus, insulin lispro for Humalog); (3) Use our price comparison tool to find which pharmacies have your insulin in stock at the lowest price.

$35

per month cap
for most patients

$0

through PAPs
if income-eligible

8.4M

Americans using
these programs

Is Insulin Free in the US?

No — insulin is not automatically free for everyone in the United States. However, as of August 2026, almost no one should pay more than $35 per month, and many patients can get it for $0 through specific programs.

Is insulin free? It depends on your situation (August 2026)
Your Situation Is It Free? Your Actual Cost
Uninsured, income ≤400% FPL Yes — through PAPs $0
Uninsured, income >400% FPL No $35/month (manufacturer programs)
Medicare beneficiary Sometimes $35/month cap (automatic)
Medicaid enrollee Often yes $0–$3/month
Commercially insured No $10–$35/month (copay cards)

The "$35 insulin" myth vs. reality: In 2023, the "Big Three" manufacturers (Lilly, Sanofi, Novo Nordisk) announced $35 price caps. What actually happened is a patchwork of programs — not a single national free-insulin policy. You must enroll in the correct manufacturer program for your specific brand. The federal government does not provide free insulin directly.

How to Get Free Insulin in 2026

If you need insulin at $0, you must apply to a Patient Assistance Program (PAP) — it is not automatic. Here's the exact path:

1

Identify your insulin's manufacturer

Check your prescription label or ask your pharmacist. Lilly makes Humalog, Basaglar, Humulin, Lyumjev, Rezvoglar. Sanofi makes Lantus, Toujeo, Admelog, Apidra. Novo Nordisk makes NovoLog, Tresiba, Fiasp.

2

Check your household income against 400% FPL

For 2026: $63,800/year for one person, $86,200 for two, $131,000 for a family of four. If you're at or below this threshold, you likely qualify for free insulin through the manufacturer's PAP.

3

Call the correct PAP line

4

Get your prescriber to complete their section

All three PAPs require your doctor to sign and confirm your diagnosis. Ask your provider's office if they have a staff member who handles PAP paperwork — many do.

5

Submit income proof and wait 2–4 weeks

Most PAPs accept a recent tax return (1040) or two recent pay stubs. If approved, medication ships directly to your home or provider's office.

Can't wait 2–4 weeks? Ask the manufacturer for an emergency one-time supply while your application processes. Also check Federally Qualified Health Centers (FQHCs) — they often provide insulin on a sliding scale down to $0–$5 per vial.

Type 1 diabetes patients: All programs listed above — Lilly Insulin Value, Sanofi Valyou, Novo Nordisk MyInsulinRx, and manufacturer PAPs — fully cover Type 1 diabetes prescriptions. There are no exclusions based on diabetes type. If you use an insulin pump, Medicare Part B's $35 cap also applies to your pump insulin.

Key Takeaways

  • $35 is the realistic ceiling — not always free, but rarely full price if you know where to look.
  • Zero deductible for Medicare: The Part D insulin cap applies automatically, with no need to meet your deductible first.
  • Uninsured patients qualify too: All three major manufacturer $35 programs explicitly cover uninsured, cash-paying patients — not just people with commercial insurance.
  • Government insurance is excluded from manufacturer cards: Medicare, Medicaid, TRICARE, and VA patients can't use the manufacturer $35 savings cards, but they have their own protections instead.
  • True $0 insulin requires a separate application to a income-based Patient Assistance Program — it isn't automatic.

Compare all 27 insulin brands side by side

Our interactive database shows cash prices, Medicare rates, savings card prices, and PAP eligibility for every insulin on the US market — filterable by manufacturer and type.

Open Insulin Price Database → Download Price CSV

On this page

For the nearly 8.4 million Americans who rely on insulin to survive, the price at the pharmacy counter has historically been a source of crushing financial stress. As of July 2026, that picture has shifted substantially — but "free insulin" still means different things depending on your insurance status, income, and which brand you take. This guide breaks down exactly what's available for Humalog, Basaglar, Lantus, Toujeo, NovoLog, and more, with specific enrollment steps for each.

1. Is Insulin Really Free? Here's the Honest Answer

Not automatically — but for many patients, effectively yes. There are two very different tiers of savings available in 2026, and knowing which one applies to you matters:

  • $35 per month: The realistic price ceiling for most insured, uninsured, and Medicare patients, through manufacturer savings programs or the federal Part D cap.
  • $0 (truly free): Available specifically through income-qualified Patient Assistance Programs (PAPs), or sometimes through Federally Qualified Health Centers on a sliding scale.

Whether you land in the $35 tier or the $0 tier comes down to four factors: your insurance status (commercial, Medicare, Medicaid, or uninsured), your household income relative to the federal poverty level, which manufacturer makes your specific insulin, and whether you have a valid, current prescription. None of these programs work automatically without you taking a step — downloading a card, calling a number, or submitting an application — so the sections below walk through exactly what to do for each brand.

2. Free Lilly Insulin: Humalog, Lyumjev, Basaglar & Rezvoglar

The Lilly Insulin Value Program caps monthly out-of-pocket costs at $35 per insulin type, and it's available to both insured and uninsured patients. It covers essentially the entire Lilly insulin lineup:

  • Humalog® (insulin lispro) — vials, KwikPens, Junior KwikPens, and Mix formulations
  • Basaglar® (insulin glargine) — KwikPen and Tempo Pen
  • Lyumjev® (fast-acting insulin lispro)
  • Rezvoglar® (insulin glargine biosimilar)
  • Humulin® R, N, and 70/30, plus generic insulin lispro

Is Eli Lilly insulin really free? Not through the $35 program itself — that caps your cost at $35, it doesn't eliminate it. For truly free Lilly insulin, income-eligible uninsured or underinsured patients can separately apply to the Lilly Cares Foundation Patient Assistance Program, which provides Humalog and other Lilly insulins at no cost to those who qualify, generally based on income at or below roughly 400% of the federal poverty level.

1

Commercially insured patients

The $35 discount is often applied automatically at participating pharmacies — no savings card required. If it isn't applied, ask your pharmacist to check for the Lilly Insulin Value Program.

2

Uninsured patients — free Lilly insulin pen access

Download the savings card at insulinaffordability.com or call the Lilly Diabetes Solution Center at 1-833-808-1234. Present the card at any participating pharmacy to pay $35 for a 30-day supply, regardless of how many vials or pens you need. This program is void for patients whose claims could be reimbursed by Medicare, Medicaid, TRICARE, or another government program.

3

Low-income and uninsured patients — Lilly Cares

Apply through Lilly Cares Foundation for potentially $0 Humalog, Basaglar, or other Lilly insulins. Your prescriber typically needs to submit part of the application alongside you.

Humulin Coupons & Savings Card 2026

Humulin — including Humulin R, Humulin N, Humulin 70/30, and the Humulin KwikPen — is covered under the same Lilly Insulin Value Program as Humalog and Basaglar. There is no separate "Humulin coupon" to hunt down.

Humulin pricing options (August 2026)
Product List Price Lilly Value Program Generic Alternative
Humulin R (vial) ~$150–$180 $35/30-day supply ~$25/vial (insulin regular)
Humulin N (vial) ~$150–$180 $35/30-day supply ~$25/vial (insulin NPH)
Humulin 70/30 (vial) ~$150–$180 $35/30-day supply ~$25/vial (insulin 70/30)
Humulin KwikPen ~$280–$350 $35/30-day supply Limited generic pen availability

How to get your Humulin coupon: Enroll in the Lilly Insulin Value Program at insulinaffordability.com or call 1-833-808-1234. The digital card works immediately at CVS, Walgreens, Walmart, and most independent pharmacies. Uninsured patients: up to 14 fills/year. Commercially insured: up to 16 fills/year.

Medicare/Medicaid patients: You cannot use the Lilly Value Program card, but Medicare's $35 insulin cap applies automatically. Medicaid typically covers Humulin at $0–$3 copay.

Basaglar Coupon & Savings Card 2026

Basaglar, Lilly's long-acting insulin glargine product, is fully included under the Lilly Insulin Value Program — there's no separate Basaglar-specific card to hunt down.

  • Who qualifies: Patients with commercial insurance or no insurance at all. You must be a US resident, 18 or older, and hold a valid prescription for Basaglar.
  • Who doesn't qualify: Patients enrolled in Medicare, Medicaid, TRICARE, VA benefits, or other government-funded healthcare programs.
  • Where to apply: insulinaffordability.com, or call 1-833-808-1234.
  • What it costs: $35 for a 30-day supply. Uninsured/cash patients: up to 14 fills/year per insulin. Commercially insured patients: up to 16 fills/year per insulin, with a $16,000 annual savings maximum.

On Medicare and taking Basaglar? You're not eligible for the manufacturer savings card, but you don't need it — the Inflation Reduction Act's Part D insulin cap already limits your Basaglar copay to $35 per month with no deductible, and a 3-month supply generally costs no more than $105 total.

Alternatives if Basaglar isn't working for you: Rezvoglar is an FDA-approved interchangeable biosimilar to Lantus-class insulin glargine, covered under the same Lilly Insulin Value Program. Unbranded insulin glargine vials and pens are also available at most pharmacies. Note: Semglee was discontinued nationwide on December 31, 2025, and is no longer available. If your pharmacy is out of Basaglar or Rezvoglar, see our Lantus shortage guide for in-stock alternatives.

Is Basaglar discontinued? No. As of August 2026, Basaglar remains in production and widely available in both KwikPen and vial formats. There have been no discontinuation announcements from Eli Lilly. If your pharmacy says Basaglar is unavailable, it is likely a localized stockout — try a different location or ask about Rezvoglar as a therapeutic alternative.

4. Humalog Cost Without Insurance: What You'll Actually Pay

Humalog's list price has fallen sharply in recent years — from as much as $274 for a single 10 mL vial down to roughly $72–$86 today. But almost no uninsured patient should be paying that list price directly. Here's the realistic cost ladder:

What Humalog actually costs without insurance, by option
OptionApprox. CostWho Qualifies
List price (no discount)~$72–$86 / vialNobody should pay this — always use a discount
Generic insulin lispro (authorized generic)~$25 / 10 mL vialAnyone, cash price, no enrollment needed
GoodRx or SingleCare couponVaries by pharmacyAnyone; compare against the $35 program
Lilly Insulin Value Program$35 / 30-day supplyUninsured or commercially insured, non-government coverage
Lilly Cares Patient Assistance$0Income-eligible uninsured/underinsured patients
Medicare Part D$35 / month, no deductibleMedicare beneficiaries (automatic)

If you're uninsured and need Humalog today, the fastest realistic path is either the $25 generic insulin lispro at any pharmacy with no signup required, or the $35 Lilly Insulin Value Program card downloaded on the spot from your phone at insulinaffordability.com.

TrumpRx: New $25/Month Insulin Option for Uninsured Patients (2026)

In February 2026, the federal government launched TrumpRx.gov as a channel-discovery platform for discounted medications. For insulin specifically, TrumpRx currently lists:

  • Insulin lispro (generic Humalog, 10 mL vial)$25 for a single vial
  • 2–4 vials of insulin lispro$35 total per month

TrumpRx partners with Amazon Pharmacy, GoodRx, and Mark Cuban's Cost Plus Drugs to fulfill orders. Unlike manufacturer savings cards, TrumpRx has no income requirements, no enrollment paperwork, and no insurance restrictions — including Medicare patients can use it (though Medicare's $35 cap usually wins).

TrumpRx vs Lilly Insulin Value Program for Uninsured Patients (2026)
FeatureLilly Insulin Value ProgramTrumpRx
Insulin lispro cost$35/month$25/vial
Brand-name Humalog$35/monthNot listed
Requires enrollmentYes — download cardNo — search and buy
Income requirementsNoneNone
Medicare eligibleNoYes
Best forPatients who want brand-name Humalog or KwikPenUninsured patients who want the lowest cash price on vials

Bottom line: If you're uninsured and your doctor approves the generic version, TrumpRx insulin lispro at $25/vial is cheaper than the Lilly $35 cap. If you specifically need brand-name Humalog or the KwikPen format, stick with the Lilly Insulin Value Program.

Lantus Cost Without Insurance & Coupons 2026

Without insurance or discounts, Lantus costs $300–$400 for a 30-day supply of SoloStar pens, or $280–$320 for a vial. Here's how to get it down to $35 or $0:

Lantus cost without insurance — all options (August 2026)
Option 30-Day Supply Cost Who Qualifies
Sanofi Insulins Valyou $35 (any income) Uninsured or commercially insured
Sanofi copay card As low as $0 Commercially insured only
Sanofi Patient Connection (PAP) $0 Uninsured, income-eligible (~400% FPL)
GoodRx / SingleCare ~$280–$350 Anyone
Medicare Part D $35/month (automatic) Medicare beneficiaries
Cash price (no discounts) ~$300–$400 Nobody should pay this
1

Get the Lantus $35 coupon

Enroll in Sanofi Insulins Valyou at lantus.com/sign-up-for-savings or call 1-800-633-1610. No income requirements. The card works for Lantus, Toujeo, Admelog, and Apidra.

2

Get Lantus for $0 (if income-eligible)

Apply to Sanofi Patient Connection at (855) 984-6302. Requires proof of income at or below roughly 400% FPL and a valid prescription.

3

If your pharmacy is out of Lantus

Intermittent SoloStar pen shortages have been reported since late 2025. Ask about Rezvoglar (interchangeable biosimilar) or unbranded insulin glargine. Lantus vials remain widely available. See our Lantus shortage guide for real-time availability.

Toujeo Free Trial & Savings 2026

There is no standalone Toujeo free trial or 30-day sample voucher as of August 2026. However, Sanofi offers two active programs that effectively serve the same purpose:

Toujeo savings options (August 2026)
Program Cost Who Qualifies
Sanofi Insulins Valyou $35/month Uninsured or commercially insured (any income)
Sanofi copay card As low as $0 Commercially insured only
Sanofi Patient Connection $0 Uninsured, income ≤400% FPL

Switching from Lantus to Toujeo: Both are insulin glargine, but Toujeo is 3x concentrated (U300 vs. U100). Your dose will be different — do not transfer your Lantus unit-for-unit to Toujeo without your prescriber's guidance.

6. NovoLog, Tresiba & Fiasp: Novo Nordisk's Savings Programs

Novo Nordisk's MyInsulinRx program covers NovoLog, Tresiba, Fiasp, and other Novo insulins at $35 for a monthly supply — up to 3 vials or 2 pen packs — plus a pack of needles for $25. It's designed specifically for uninsured patients and re-enrollment is required every calendar year.

  • Uninsured patients: Text ENROLL to 24177, or visit novocare.com, to register for MyInsulinRx.
  • Commercially insured patients: A separate NovoLog savings card can bring your cost to as little as $35 per 30-day supply, with maximum savings of $65 per fill — not valid for Medicare or Medicaid.
  • Free NovoLog or Fiasp: Income-eligible uninsured patients can apply to the Novo Nordisk Patient Assistance Program for medication at no cost. 2026 update: Approved medication now ships directly to your home via Neovance Specialty Pharmacy (not your doctor's office). Call 1-866-310-7549 or apply online at NovoCare. Medicare patients can also apply, but the application deadline is November 30 each year.

If you are also prescribed Ozempic and want it delivered, see our complete guide to Ozempic mail order in 2026, including NovoCare Pharmacy's self-pay option from $199/month with free shipping. Ozempic patients can also get home delivery from $199/month.

Novo Nordisk $35 Insulin Card: MyInsulinRx 2026

Novo Nordisk's MyInsulinRx is the manufacturer's $35 insulin card for uninsured patients. It covers NovoLog, Tresiba, Fiasp, and Levemir — up to 3 vials or 2 pen packs per month — plus a pack of needles for $25.

Novo Nordisk MyInsulinRx details (August 2026)
Feature Details
Monthly cost $35 for up to 3 vials or 2 pen packs
Needles $25 per pack (optional add-on)
Who qualifies Uninsured or commercially insured patients
Who is excluded Medicare, Medicaid, TRICARE, VA, DOD
Re-enrollment Required every calendar year
How to enroll Text ENROLL to 24177 or visit novocare.com
Phone 1-866-310-7549

MyInsulinRx vs. Novo Nordisk PAP: The $35 card is for any uninsured or commercially insured patient — no income test. The Novo Nordisk Patient Assistance Program provides medication at $0 but requires income at or below 400% FPL. If you don't qualify for the PAP, the $35 card is your fallback.

Levemir note: Levemir was discontinued in the US at the end of 2024 and is no longer manufactured. If you were previously receiving Levemir through MyInsulinRx, contact NovoCare at 1-866-310-7549 to transition to Tresiba or another basal insulin.

7. Which Insulin Brands Have Free or $35 Programs?

Here's the full picture across the major insulin brands, so you can jump straight to what applies to your prescription.

Insulin brand savings programs at a glance (2026)
BrandManufacturer$35 Savings CardPatient Assistance (Free)Medicare $35 Cap
HumalogLillyYesYesYes
BasaglarLillyYesYesYes
LyumjevLillyYesYesYes
RezvoglarLillyYesYesYes
LantusSanofiYesYesYes
ToujeoSanofiYesYesYes
Admelog / ApidraSanofiYesYesYes
NovoLogNovo NordiskYesYesYes
Tresiba / FiaspNovo NordiskYesYesYes
Soliqua (combo)SanofiExcluded from ValyouYes (Patient Connection)Yes

How Much Does Insulin Cost Without Insurance in 2026?

Without insurance or discounts, insulin is expensive. Here's what you'll actually pay at the pharmacy counter, and how to get it cheaper:

Insulin cash prices vs. discount prices (August 2026)
Insulin List/Cash Price With Manufacturer Program Cheapest Path
Humalog (vial) ~$72–$86 $35 (Lilly Value Program) ~$25 generic lispro (TrumpRx)
Basaglar (KwikPen) ~$280–$350 $35 (Lilly Value Program) $35 (uninsured eligible)
Lantus (SoloStar) ~$300–$400 $35 (Sanofi Valyou) $35 (any income)
Lantus (vial) ~$280–$320 $35 (Sanofi Valyou) $35 (any income)
NovoLog (vial) ~$300–$350 $35 (MyInsulinRx) $35 (uninsured eligible)
Tresiba (pen) ~$400–$500 $35 (MyInsulinRx) $35 (uninsured eligible)
Rezvoglar (biosimilar) ~$250–$300 $35 (Lilly Value Program) $35 (uninsured eligible)

Annual savings example: A patient taking Lantus at full retail (~$350/month) would spend $4,200/year. Through Sanofi Valyou, the same patient pays $420/year — a $3,780 savings. If income-eligible for Sanofi Patient Connection, the cost drops to $0.

$35
realistic monthly ceiling across nearly every major insulin brand
$0
deductible required before the Medicare Part D insulin cap applies
400%
FPL — typical income ceiling for free Patient Assistance Program eligibility

8. Medicare Part D in 2026: The $35 Cap Explained

If you're on Medicare, this is the most important section for you: the Inflation Reduction Act's insulin provisions are fully in effect and don't require you to sign up for anything.

  • $35 statutory cap: Every Part D plan must cap insulin copays at $35 for a 30-day supply of each covered insulin product.
  • No deductible required: The cap applies from your very first fill of the year, even if you haven't met your plan's annual deductible.
  • Covers Part B insulin too: If you use an insulin pump covered under Medicare Part B, the same $35 cap applies to insulin used with that pump.
  • No manufacturer card needed — or allowed: Because the cap is automatic, you don't need (and generally can't use) a manufacturer's $35 savings card on top of Medicare.
  • Smoothing option: If your insulin costs still feel front-loaded, ask about the Medicare Prescription Payment Plan, which spreads your out-of-pocket drug costs evenly across the year.

9. The "Hidden" Safety Net: 340B Clinics and FQHCs

Federally Qualified Health Centers (FQHCs) purchase insulin through the federal 340B drug pricing program at steep discounts, then pass those savings to patients through an income-based sliding scale. If you become a patient at an FQHC, your cost for insulin can come down to $0 to $5 per vial, depending on your income. You can find a nearby FQHC through HRSA's official health center locator. This route is worth pursuing if you're uninsured and don't yet qualify for — or are still waiting on approval for — a manufacturer Patient Assistance Program.

10. Emergency Access: State Laws and Charitable Options

If you're out of insulin today and can't wait for an application to process, several safety nets exist specifically for that situation:

  • Manufacturer "urgent need" access: All three major manufacturers can provide an emergency one-time supply while you enroll in a longer-term program — call the numbers listed above and explain you have an urgent need.
  • State emergency-supply laws: Minnesota's Alec Smith Insulin Affordability Act provides a 30-day emergency supply for a capped cost to residents in urgent need; more than 20 other states have passed similar insulin emergency-access or price-cap laws. Note that self-funded employer health plans are often exempt from state caps due to federal ERISA preemption, so check whether your plan is state-regulated or self-funded.
  • Charitable redistribution: Nonprofits like Insulin for Life USA redistribute unexpired, unused insulin donated by other patients to people in genuine need, free of charge.

People Also Ask (FAQ)

Sometimes, but not automatically. It can be free through manufacturer Patient Assistance Programs for people who meet income requirements, typically around 400% of the federal poverty level. Otherwise, most patients — insured or not — can access $35/month pricing through manufacturer savings programs or the Medicare Part D insulin cap.

Apply to the Patient Assistance Program for your specific brand: Lilly Cares for Humalog/Basaglar/Lyumjev, Sanofi Patient Connection for Lantus/Toujeo, or Novo Nordisk's PAP for NovoLog/Tresiba/Fiasp. Most require proof of income under roughly 400% FPL and a valid prescription. FQHCs can also offer sliding-scale pricing down to $0–$5.

Uninsured patients have three paths to free or $35 insulin: (1) Manufacturer $35 programs — Lilly Insulin Value Program, Sanofi Valyou, and Novo Nordisk MyInsulinRx all explicitly accept uninsured patients with a valid prescription; (2) Patient Assistance Programs — Lilly Cares, Sanofi Patient Connection, and Novo Nordisk PAP provide free insulin to income-eligible uninsured patients, typically at or below 400% of the federal poverty level; (3) Federally Qualified Health Centers — offer insulin on a sliding scale, sometimes as low as $0–$5 per vial.

Not automatically. The Lilly Insulin Value Program caps Lilly insulins at $35/month for insured or uninsured patients. For $0 insulin, income-eligible uninsured or underinsured patients must separately apply to the Lilly Cares Foundation Patient Assistance Program. Government-insured patients (Medicare, Medicaid) don't qualify for the $35 card.

Lantus is $35 for a 30-day supply through Sanofi's Insulins Valyou Savings Program, open to any income level. For truly free Lantus, income-eligible uninsured or underinsured patients can apply to Sanofi Patient Connection. Commercially insured patients may also qualify for a separate copay card that can bring costs as low as $0.

Yes. Every Medicare Part D plan caps insulin copays at $35 for a 30-day supply, with no deductible required, under the Inflation Reduction Act. This applies automatically and also extends to insulin used with a Part B-covered insulin pump.

You're specifically eligible for the same $35 manufacturer programs as insured patients — the Lilly Insulin Value Program, Sanofi Valyou, and Novo Nordisk's MyInsulinRx all explicitly cover uninsured, cash-paying patients. If $35 is still unaffordable, income-eligible uninsured patients can apply for free insulin through Patient Assistance Programs.

Not automatically — Humalog is capped at $35/month for insured and uninsured patients through the Lilly Insulin Value Program. It can be free for low-income patients through the Lilly Cares Foundation Patient Assistance Program.

Yes. Unlike traditional copay cards, the major $35 insulin programs (Lilly, Sanofi, Novo Nordisk) are specifically built to work for uninsured, cash-paying patients, not just those with commercial insurance. They're not valid for Medicare, Medicaid, TRICARE, or VA coverage.

No. Lantus has not been discontinued. Intermittent shortages of the SoloStar pen format have been reported since late 2025, but Lantus vials remain widely available. The confusion stems from the Semglee discontinuation on December 31, 2025 — Semglee was a biosimilar, not Lantus itself. If your pharmacy is out of Lantus pens, ask about Rezvoglar (interchangeable biosimilar) or unbranded insulin glargine.

Without insurance or discounts, brand-name insulin costs $280–$500 per month. However, manufacturer programs cap most insulins at $35/month for uninsured patients: Lilly Insulin Value Program (Humalog, Basaglar), Sanofi Valyou (Lantus), and Novo Nordisk MyInsulinRx (NovoLog, Tresiba). Generic insulin lispro costs approximately $25/vial through TrumpRx. Income-eligible patients can get insulin for $0 through Patient Assistance Programs.

Yes, intermittent shortages of Lantus SoloStar pens have been reported since late 2025 following the Semglee discontinuation. Lantus vials remain more widely available. Supply varies by pharmacy chain and region. If your pharmacy is out of stock, ask about Rezvoglar (the authorized biosimilar) or unbranded insulin glargine as alternatives. See our Lantus shortage guide for current availability.

No — not automatically. Insulin can be $0 through manufacturer Patient Assistance Programs if your household income is at or below roughly 400% of the federal poverty level. For most other patients, the realistic ceiling is $35 per month through manufacturer savings programs or Medicare's Part D cap. There is no federal program that provides free insulin to all Americans.

Without insurance or discounts, Lantus costs approximately $300–$400 per month for SoloStar pens, or $280–$320 for a vial. Through the Sanofi Insulins Valyou Savings Program, uninsured patients pay $35/month regardless of income. Income-eligible patients can get Lantus for $0 through Sanofi Patient Connection.

Humalog's list price is roughly $72–$86 per 10 mL vial, but retail pharmacies often charge more. Through the Lilly Insulin Value Program, uninsured patients pay $35/month. Generic insulin lispro costs approximately $25/vial with no enrollment required. Income-eligible patients can get Humalog for $0 through Lilly Cares.

There is no standalone printable Basaglar coupon. Basaglar is capped at $35/month through the Lilly Insulin Value Program, available to uninsured and commercially insured patients. Enroll at insulinaffordability.com or call 1-833-808-1234. Uninsured patients get up to 14 fills per year.

Yes — Humulin R, Humulin N, Humulin 70/30, and Humulin KwikPen are all covered under the Lilly Insulin Value Program at $35 per 30-day supply. There is no separate Humulin coupon. Enroll at insulinaffordability.com. Generic human insulin (regular, NPH, 70/30) is also available for approximately $25/vial without enrollment.

The Novo Nordisk MyInsulinRx program is the manufacturer's $35 insulin card for uninsured patients. It covers NovoLog, Tresiba, and Fiasp — up to 3 vials or 2 pen packs per month for $35. Enroll by texting ENROLL to 24177 or visiting novocare.com. Medicare, Medicaid, and TRICARE patients are ineligible.

Apply to the Patient Assistance Program for your insulin's manufacturer: Lilly Cares (1-800-545-6962) for Humalog/Basaglar/Humulin, Sanofi Patient Connection (1-855-984-6302) for Lantus/Toujeo, or Novo Nordisk PAP (1-866-310-7549) for NovoLog/Tresiba. Most require income at or below 400% FPL (~$63,800/year for one person) and a valid prescription. You can also visit a Federally Qualified Health Center for sliding-scale pricing as low as $0–$5.

Disclaimer: This guide reflects manufacturer program terms and Medicare rules as of July 29, 2026. It does not constitute medical advice. Program eligibility, pricing, and terms can change without notice — confirm current details directly with Lilly, Sanofi, Novo Nordisk, or Medicare before enrolling. Always consult a healthcare professional regarding your specific diabetes management.

Evan Brown
About the Author
Evan Brown — Prescription Savings Researcher

Evan Brown is a prescription savings researcher who specializes in translating complex healthcare and pharmacy benefit information into clear, actionable guidance for patients.

View Full Profile →
Dr. Megan Harris, MD
Medical Review
Dr. Megan Harris, MD — Board-Certified Internal Medicine

Dr. Megan Harris, MD reviews health content for medical accuracy and evidence-based information.

View Full Profile →

Contact Refill Relay